Literature DB >> 28970291

Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.

Yong Lv1, Xingshun Qi1, Chuangye He1, Zhengyu Wang1, Zhanxin Yin1, Jing Niu, Wengang Guo1, Wei Bai1, Hongbo Zhang2, Huahong Xie2, Liping Yao2, Jianhong Wang3, Tao Li3, Qiuhe Wang1, Hui Chen1, Haibo Liu1, Enxing Wang1, Dongdong Xia1, Bohan Luo1, Xiaomei Li1, Jie Yuan1, Na Han1, Ying Zhu1, Jielai Xia4, Hongwei Cai4, Zhiping Yang5, Kaichun Wu5, Daiming Fan5, Guohong Han1.   

Abstract

OBJECTIVE: Limited data are available on the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis (PVT). This study aimed to compare transjugular intrahepatic portosystemic shunt (TIPS) with covered stents versus endoscopic band ligation (EBL) plus propranolol for the prevention of variceal rebleeding among patients with cirrhosis and PVT.
DESIGN: Consecutive cirrhotic patients (94% Child-Pugh class A or B) with PVT who had variceal bleeding in the past 6 weeks were randomly assigned to TIPS group (n=24) or EBL plus propranolol group (EBL+drug, n=25), respectively. Primary endpoint was variceal rebleeding. Secondary endpoints included survival, overt hepatic encephalopathy (OHE), portal vein recanalisation and rethrombosis, other complications of portal hypertension and adverse events.
RESULTS: During a median follow-up of 30 months in both groups, variceal rebleeding was significantly less frequent in the TIPS group (15% vs 45% at 1 year and 25% vs 50% at 2 years, respectively; HR=0.28, 95% CI 0.10 to 0.76, p=0.008), with a significantly higher portal vein recanalisation rate (95% vs 70%; p=0.03) and a relatively lower rethrombosis rate (5% vs 33%; p=0.06) compared with the EBL+drug group. There were no statistically significant differences in survival (67% vs 84%; p=0.152), OHE (25% vs 16%; p=0.440), other complications of portal hypertension and adverse events between groups.
CONCLUSION: Covered TIPS placement in patients with PVT and moderately decompensated cirrhosis was more effective than EBL combined with propranolol for the prevention of rebleeding, with a higher probability of PVT resolution without increasing the risk of OHE and adverse effects, but this benefit did not translate into improved survival. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT01326949. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  endoscopy; interventional radiology; liver Cirrhosis; portal hypertension; venous thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28970291     DOI: 10.1136/gutjnl-2017-314634

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  31 in total

1.  Timing of the Treatment of Portal Vein Thrombosis in Patients with Cirrhosis: A German Hepatologist's Perspective.

Authors:  Martin Rössle; Michael Schultheiss
Journal:  J Transl Int Med       Date:  2018-03-28

2.  Emergency Transjugular Intrahepatic Portosystemic Shunt: an Effective and Safe Treatment for Uncontrolled Variceal Bleeding.

Authors:  Yongjun Zhu; Xiaoze Wang; Xiaotan Xi; Xiao Li; Xuefeng Luo; Li Yang
Journal:  J Gastrointest Surg       Date:  2019-02-21       Impact factor: 3.452

3.  Comparison of transjugular intrahepatic portosystemic shunt (TIPS) alone and combined with embolisation for the management of cardiofundal varices: a retrospective study.

Authors:  Jiaze Yu; Xiaoze Wang; Mingshan Jiang; Huaiyuan Ma; Zilin Zhou; Li Yang; Xiao Li
Journal:  Eur Radiol       Date:  2018-07-23       Impact factor: 5.315

4.  Computed tomography-based score model/nomogram for predicting technical and midterm outcomes in transjugular intrahepatic portosystemic shunt treatment for symptomatic portal cavernoma.

Authors:  Xiang-Ke Niu; Sushant Kumar Das; Hong-Lin Wu; Yong Chen
Journal:  World J Clin Cases       Date:  2020-03-06       Impact factor: 1.337

5.  Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study.

Authors:  Yang Yang; Sirui Fu; Bin Cao; Kenan Hao; Yong Li; Jianwen Huang; Wenfeng Shi; Chongyang Duan; Xiao Bai; Kai Tang; Shirui Yang; Xiaofeng He; Ligong Lu
Journal:  Hepatol Int       Date:  2021-05-11       Impact factor: 6.047

Review 6.  Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai).

Authors: 
Journal:  J Dig Dis       Date:  2021-03-07       Impact factor: 2.325

7.  Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis.

Authors:  Maria Corina Plaz Torres; Lawrence Mj Best; Suzanne C Freeman; Danielle Roberts; Nicola J Cooper; Alex J Sutton; Davide Roccarina; Amine Benmassaoud; Laura Iogna Prat; Norman R Williams; Mario Csenar; Dominic Fritche; Tanjia Begum; Sivapatham Arunan; Maxine Tapp; Elisabeth Jane Milne; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-03-30

8.  Portal vein thrombosis associated with high 14-day and 6-week rebleeding in patients after oesophageal variceal band ligation: a retrospective, multicentre, nested case-control study.

Authors:  Zhanjuan Gao; Jingrun Zhao; Xiaofeng Liu; Senlin Li; Minghui Wang; Yanjing Gao
Journal:  Hepatol Int       Date:  2021-07-22       Impact factor: 6.047

9.  Potential Benefits of Underdilation of 8-mm Covered Stent in Transjugular Intrahepatic Portosystemic Shunt Creation.

Authors:  Jiacheng Liu; Jinqiang Ma; Chen Zhou; Chongtu Yang; Songjiang Huang; Qin Shi; Bin Xiong
Journal:  Clin Transl Gastroenterol       Date:  2021-06-18       Impact factor: 4.488

10.  Systematic review and meta-analysis of trans-jugular intrahepatic portosystemic shunt for cirrhotic patients with portal vein thrombosis.

Authors:  Jian-Bin Zhang; Jie Chen; Jin Zhou; Xu-Ming Wang; Shu Chen; Jian-Guo Chu; Peng Liu; Zhi-Dong Ye
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.